MR/W003988/1/MRC_/Medical Research Council/United Kingdom[Grants and Funding] - Search Results

Year	Number of Results
2022	6
2023	7
2024	1

1

Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes.

Nair ATN, Wesolowska-Andersen A, Brorsson C, Rajendrakumar AL, Hapca S, Gan S, Dawed AY, Donnelly LA, McCrimmon R, Doney ASF, Palmer CNA, Mohan V, Anjana RM, Hattersley AT, Dennis JM, Pearson ER. Nair ATN, et al. Nat Med. 2022 May;28(5):982-988. doi: 10.1038/s41591-022-01790-7. Epub 2022 May 9. Nat Med. 2022. PMID: 35534565

2

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy.

Young KG, Hopkins R, Shields BM, Thomas NJ, McGovern AP, Dennis JM; MASTERMIND consortium. Young KG, et al. Cardiovasc Diabetol. 2023 Nov 2;22(1):302. doi: 10.1186/s12933-023-02032-x. Cardiovasc Diabetol. 2023. PMID: 37919773 Free PMC article.

3

Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches.

Thomas NJ, McGovern A, Young KG, Sharp SA, Weedon MN, Hattersley AT, Dennis J, Jones AG. Thomas NJ, et al. J Clin Epidemiol. 2023 Jan;153:34-44. doi: 10.1016/j.jclinepi.2022.10.022. Epub 2022 Nov 9. J Clin Epidemiol. 2023. PMID: 36368478 Free article.

4

Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.

Cardoso P, Young KG, Nair ATN, Hopkins R, McGovern AP, Haider E, Karunaratne P, Donnelly L, Mateen BA, Sattar N, Holman RR, Bowden J, Hattersley AT, Pearson ER, Jones AG, Shields BM, McKinley TJ, Dennis JM; MASTERMIND consortium. Cardoso P, et al. Diabetologia. 2024 May;67(5):822-836. doi: 10.1007/s00125-024-06099-3. Epub 2024 Feb 22. Diabetologia. 2024. PMID: 38388753 Free PMC article.

5

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.

Young KG, McInnes EH, Massey RJ, Kahkoska AR, Pilla SJ, Raghavan S, Stanislawski MA, Tobias DK, McGovern AP, Dawed AY, Jones AG, Pearson ER, Dennis JM; ADA/EASD PDMI. Young KG, et al. Commun Med (Lond). 2023 Oct 5;3(1):131. doi: 10.1038/s43856-023-00359-w. Commun Med (Lond). 2023. PMID: 37794166 Free PMC article.

6

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study.

Shields BM, Dennis JM, Angwin CD, Warren F, Henley WE, Farmer AJ, Sattar N, Holman RR, Jones AG, Pearson ER, Hattersley AT; TriMaster Study group. Shields BM, et al. Nat Med. 2023 Feb;29(2):376-383. doi: 10.1038/s41591-022-02120-7. Epub 2022 Dec 7. Nat Med. 2023. PMID: 36477733 Free PMC article. Clinical Trial.

7

Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.

Dennis JM, Young KG, McGovern AP, Mateen BA, Vollmer SJ, Simpson MD, Henley WE, Holman RR, Sattar N, Pearson ER, Hattersley AT, Jones AG, Shields BM; MASTERMIND consortium. Dennis JM, et al. Lancet Digit Health. 2022 Dec;4(12):e873-e883. doi: 10.1016/S2589-7500(22)00174-1. Lancet Digit Health. 2022. PMID: 36427949 Free article.

8

Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine.

Venkatasubramaniam A, Mateen BA, Shields BM, Hattersley AT, Jones AG, Vollmer SJ, Dennis JM. Venkatasubramaniam A, et al. BMC Med Inform Decis Mak. 2023 Jun 16;23(1):110. doi: 10.1186/s12911-023-02207-2. BMC Med Inform Decis Mak. 2023. PMID: 37328784 Free PMC article.

9

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.

Shields BM, Angwin CD, Shepherd MH, Britten N, Jones AG, Sattar N, Holman R, Pearson ER, Hattersley AT. Shields BM, et al. Nat Med. 2023 Feb;29(2):384-391. doi: 10.1038/s41591-022-02121-6. Epub 2022 Dec 7. Nat Med. 2023. PMID: 36477734 Free PMC article. Clinical Trial.

10

The impact of population-level HbA_1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis.

Young KG, McGovern AP, Barroso I, Hattersley AT, Jones AG, Shields BM, Thomas NJ, Dennis JM. Young KG, et al. Diabetologia. 2023 Feb;66(2):300-309. doi: 10.1007/s00125-022-05824-0. Epub 2022 Nov 22. Diabetologia. 2023. PMID: 36411396 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year